The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Questions about liquid biopsy & the latest longevity debate

By Damian Garde

The READOUT
The Readout

Parsing Pfizer’s $11B deal & a big IPO week

By Damian Garde

The READOUT
The Readout

China’s U.S. bio-recruits & exploring AI for novel drugs

By Meghana Keshavan

The READOUT
The Readout

A sickle-cell debate & the legalities of biohacking

By Damian Garde

The READOUT
The Readout

GSK’s CRISPR inroads & panic over China genomics

By Damian Garde

The READOUT
The Readout

The need-to-know on KRAS & more NASH drama

By Damian Garde

The READOUT
The Readout

The next big biotech IPO & Bluebird’s pricey decision

By Damian Garde

The READOUT
The Readout

Progress in diabetes & a new Sanofi CEO

By Meghana Keshavan

The Readout

Small-cap biotech: TORC, TROV and ATOS

By Damian Garde

The READOUT
The Readout

Hans Bishop moves to Grail & pharma sandbagging

By Damian Garde

The READOUT
The Readout

Inside Biogen’s Alzheimer’s failure & a victory for biotech bears

By Damian Garde

The READOUT
The Readout

Bristol execs on the move & the sound of ASCO

By Damian Garde

The READOUT
The Readout

FDA ‘acting’ lessons & the stars of ASCO

By Damian Garde

The READOUT
The Readout

Moderna’s first data & toga parties and BIO(tech)

By Meghana Keshavan

The READOUT
The Readout

Why DTC genetics is hard & the costly oncology boom

By Damian Garde

The READOUT
The Readout

The latest liquid biopsy contender & Merck’s big weekend

By Damian Garde

The READOUT
The Readout

Celgene’s next test & biopharma’s income gap

By Damian Garde

The READOUT
The Readout

A Zolgensma frenzy & an AstraZeneca reboot

By Meghana Keshavan

The READOUT
The Readout

MIT’s bitter biotech debate & Sarepta’s latest controversy

By Damian Garde

The READOUT
The Readout

Google’s designs on biotech & Novartis’s mystery gene therapy price

By Damian Garde

The READOUT
The Readout

Verily moves into clinical trials & an about-face for Peloton

By Damian Garde

The READOUT
The Readout

Relitigating amyloid & the (new) debate over PCSK9

By Damian Garde

The READOUT
The Readout

PatientsLikeMe founder has his say & a CRISPR debrief

By Meghana Keshavan

The READOUT
The Readout

Health tech ethics & Gilead’s Capitol punishment

By Damian Garde

The READOUT
The Readout

Drugging the ‘undruggable’ & fraying bipartisanship

By Damian Garde

The READOUT
The Readout

Bad receptions for good data & a CRISPR need-to-know

By Damian Garde

The READOUT
The Readout

The benefits of banality & Solid Bio’s hiccup

By Damian Garde

The READOUT
The Readout

Rampant pricing collusion & a bumper crop of biotech IPOs

By Damian Garde

The READOUT
The Readout

A laissez-faire SEC & why selling gene therapy is hard

By Damian Garde

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy